Overview
5-Amino-1MQ is a selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for potential benefits including “fat metabolism support, lean muscle preservation, and elevated intracellular NAD+ levels.” This compound works by blocking an enzyme that methylates nicotinamide, thereby restoring cellular energy balance and activating metabolic pathways.
Mechanism of Action
The compound selectively inhibits NNMT, an enzyme that depletes nicotinamide in obesity-related metabolic dysfunction. By preventing this depletion, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, potentially activating SIRT1 pathways linked to mitochondrial biogenesis and fat oxidation. Research suggests NNMT inhibition can protect against diet-induced weight gain without reducing food intake.
Dosage Protocol
Reconstitution
– Amount: Add 4.0 mL bacteriostatic water to the 50 mg vial
– Final concentration: 12.5 mg/mL
– Measurement: 1 unit on U-100 insulin syringe = 0.125 mg (125 mcg)
Dosing Schedule
| Phase | Daily Dose | Units per Injection |
|---|---|---|
| Days 1-2 (Tolerance) | 2.5 mg once daily | 20 units (0.20 mL) |
| Days 3+ (Standard) | 5 mg once daily | 40 units (0.40 mL) |
| Alternative BID | 2.5 mg twice daily | 20 units × 2 daily |
Frequency: Once or twice daily via subcutaneous injection. The compound has a plasma half-life of approximately 3.8–6.9 hours, making twice-daily dosing potentially beneficial for sustained NNMT inhibition.
Vial Duration: A single 50 mg vial provides 10–20 days of research material at these doses.
Reconstitution Instructions
1. Remove vial from freezer storage (−20 °C / −4 °F) and allow 15–20 minutes to reach room temperature
2. Draw 4.0 mL bacteriostatic water with sterile syringe
3. Inject slowly down the vial wall, avoiding foam formation
4. Gently swirl or roll until completely dissolved—solution should be clear
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light
6. Use within 2–4 weeks of reconstitution
Storage
Lyophilized form: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months
Reconstituted solution: Refrigerate at 2–8 °C (35.6–46.4 °F); do not refreeze
Allow vials to reach room temperature before reconstitution to prevent condensation and pressure complications.
Supplies Needed
For 4-Week Protocol (5 mg/day)
– 2 vials of 5-Amino-1MQ (50 mg each)
– 28 U-100 insulin syringes (once daily dosing)
– 8 mL bacteriostatic water (1 × 10 mL bottle)
– 56 alcohol swabs (1 × 100-count box recommended)
Injection Technique
– Clean vial stopper and injection site with alcohol; allow to dry completely
– Pinch a skinfold and insert needle at 45–90° angle into subcutaneous tissue
– Do not aspirate for subcutaneous injections
– Inject slowly and steadily to minimize stinging sensation
– Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy
– Use new sterile syringes for each administration; dispose in sharps container
Potential Benefits
Research indicates the compound may:
– Support reductions in fat mass while preserving lean muscle in animal models
– Elevate NAD+ levels and activate SIRT1 in preclinical studies
– Enhance grip strength in aged mice when combined with exercise
– Generally be well tolerated with minimal adverse effects
Side Effects & Considerations
Common observations: Occasional reports of mild headache, transient jitteriness, or injection-site reactions
Important note: Long-term human safety data has not been established; this compound remains investigational and should only be used for research purposes.
Complementary Strategies
– Combine with balanced, protein-forward nutrition tailored to energy requirements
– Pair with resistance training and aerobic activity for potential synergistic benefits
– Prioritize adequate sleep and stress management to support metabolic adaptation
– Consider complementary NAD+ precursors (NMN/NR) per emerging research protocols
Key Warnings
This protocol is “for educational purposes only and is not medical advice” or medical treatment guidance. Research use only; not for human consumption. Consult qualified healthcare professionals before beginning any research protocol. No human clinical trials of this compound have been published to date.